Browsing by Author Ho, Joy Phoebe

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 15 of 15
Issue DateTitleAuthor(s)Citation
2016A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subsetBradstock, Kenneth; Bryant, Christian; Clark, Georgina; Fromm, Phillip; Hart, Derek; Ho, Joy Phoebe; Joshua, Douglas; Lee, Kenneth; Silveira, Pablo; Brown, Ross D.; Clarke, Candice; Cunningham, Ilona; Gibson, John; Kupresanin, Fiona; Newman, Elizabeth; Suen, Hayley; Western Clinical School: Westmead Institute for Medical Res; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteA CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset, Immunology and Cell Biology, vol.94, 5, 2016,pp 447-457
2016A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subsetBradstock, Kenneth; Bryant, Christian; Clark, Georgina; Fromm, Phillip; Hart, Derek; Ho, Joy Phoebe; Joshua, Douglas; Lee, Kenneth; Silveira, Pablo; Brown, Ross D.; Clarke, Candice; Cunningham, Ilona; Gibson, John; Kupresanin, Fiona; Newman, Elizabeth; Suen, Hayley; Western Clinical School: Westmead Institute for Medical Res; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteA CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset, Immunology and Cell Biology, vol.94, 5, 2016,pp 447-457
2016Haemoglobin disorders in Australia: where are we now and where will we be in the future?Ho, Joy Phoebe; Bowden, Donald; Crighton, Gemma L; Scarborough, R; Wood, Erica M; Central Clinical School: MedicineHaemoglobin disorders in Australia: where are we now and where will we be in the future?, Internal Medicine Journal, vol.46, 7, 2016,pp 770-779
2015The impact of sputum quality on tuberculosis diagnosis: a systematic reviewFox, Gregory; Ho, Joy Phoebe; Marks, Guy; Central Clinical School: Woolcock Inst. of Medical Research; Central Clinical School: Medicine; Central Clinical School: Woolcock Inst. of Medical ResearchThe impact of sputum quality on tuberculosis diagnosis: a systematic review, International Journal of Tuberculosis and Lung Disease, vol.19, 5, 2015,pp 537-544
2015Management of Systemic AL Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupHo, Joy Phoebe; Augustson, B; Brown, R; Catley, Laurence; Douglas, Joshua; et al, Various; Gibson, J; Harrison, S; Horvath, N; Jaksic, W; Mollee, P.; Quach, H; Weber, N; Central Clinical School: MedicineManagement of Systemic AL Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group, Internal Medicine Journal, vol.45, 4, 2015,pp 371-382
2016Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockadeBryant, Catherine; Gibson, John; Hart, Derek; Ho, Joy Phoebe; Joshua, Douglas; Weatherburn, Claire; Barbaro, P; Brown, Ross D.; Nassif, Najah T; Suen, Hayley; Woodland, N. B.; Yang, Shihong; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineMultiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade, Leukemia, vol.30, 8, 2016,pp 1716-1724
2016Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockadeBryant, Catherine; Gibson, John; Hart, Derek; Ho, Joy Phoebe; Joshua, Douglas; Weatherburn, Claire; Barbaro, P; Brown, Ross D.; Nassif, Najah T; Suen, Hayley; Woodland, N. B.; Yang, Shihong; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineMultiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade, Leukemia, vol.30, 8, 2016,pp 1716-1724
2014Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive stateFromm, Phillip; Hart, Derek; Ho, Joy Phoebe; Joshua, Douglas; Aklilu, Esther; Brown, Ross; Favaloro, James; Gibson, John; Khoo, Liane; Suen, Hayley; Yang, Shihong; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: MedicineMyeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state, Leukemia & Lymphoma, vol.55, 5, 2014,pp 1090-1098
2017Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I studyHo, Joy Phoebe; Bhutani, Divaya; Gyger, M; Inamdar, S; Morris, C; Ou, Y; Quach, Hang; Spencer, Andrew; White, D; White, M; Central Clinical School: MedicinePharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study, Cancer Chemotherapy and Pharmacology, vol.79, 6, 2017,pp 1067-1076
2015Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myelomaHart, Derek; Ho, Joy Phoebe; Joshua, Douglas; Brown, R. D.; Gibson, J; Suen, Hayley; Weatherburn, Claire; Yang, S; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: MedicinePhospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma, Leukemia, vol.29, 2, 2015,pp 483-490
2017Pooling sputum samples to improve the feasibility of Xpert(®) MTB/RIF in systematic screening for tuberculosisFox, Gregory; Ho, Joy Phoebe; Jelfs, Peter; Marks, Guy; Sintchenko, Vitali; Nguyen, Patrick T.B; Central Clinical School: Woolcock Inst. of Medical Research; Central Clinical School: Medicine; Medicine; Central Clinical School: Woolcock Inst. of Medical Research; Western Clinical School: Medicine (Westmead)Pooling sputum samples to improve the feasibility of Xpert(®) MTB/RIF in systematic screening for tuberculosis, International Journal of Tuberculosis and Lung Disease, vol.21, 5, 2017,pp 503-508
2015Practical management of myelofibrosis with ruxolitinibHo, Joy Phoebe; Stevenson, William; Bird, Robert; Dunlop, L; Durrant, S; Marlton, Paula V; Ritchie, D; Ross, David M; Tam, Constantine; Central Clinical School: Medicine; Northern Clinical School: MedicinePractical management of myelofibrosis with ruxolitinib, Internal Medicine Journal, vol.45, 12, 2015,pp 1221-1230
2015Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupGibson, John; Ho, Joy Phoebe; Joshua, Douglas; Augustson, Bradley M.; Brown, R. D.; Catley, Andrew; Harrison, Simon James; Horvath, Noemi; Jaksic, M; Mollee, P.; Prince, H.Miles; Quach, Hang; Roberts, A W; Spencer, A.; Szer, J; Talulikar, D; To, KF; Zannettino, A; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineTreatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group, Internal Medicine Journal, vol.45, 1, 2015,pp 94-105
2015Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory GroupGibson, John; Ho, Joy Phoebe; Joshua, Douglas; et al, Various; Harrison, Simon James; Horvath, Noemi; Mollee, Peter N; Quach, Hang; Roberts, Andrew; Spencer, Andrew; Szer, Jeff; Talaulikar, Dipti; To, B; Zannettino, Andrew C W; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineTreatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group, Internal Medicine Journal, vol.45, 3, 2015,pp 335-343
2017Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupGibson, John; Ho, Joy Phoebe; Joshua, Douglas; Trotman, Judith; Ward, Christopher; et al, Various; Harrison, Simon; Horvath, Noemi; Lee, Cindy; Mollee, Peter N; Quach, Hang; Roberts, Andrew; Spencer, Andrew; Szer, Jeff; Talaulikar, Dipti; Tam, Constantine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: Medicine; Northern Clinical School: Kolling InstituteTreatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group, Internal Medicine Journal, vol.47, 1, 2017,pp 35-49